Company coronavirus news summary – Relief, NeuroRx complete enrolment for critical Covid-19 drug trial – Canada doubles its vaccine supply agreement with Moderna

8 December 2020 (Last Updated December 8th, 2020 09:02)

8 December 2020

Chinese vaccine developer Sinovac Life Sciences announced that it has secured $500m in funding from Sino Biopharmaceutical to develop, manufacture, and increase capacity of CoronaVac, its Covid-19 vaccine candidate. Weidong Yin, the president and CEO of Sinovac stated that the coronavirus vaccine has achieved critical milestones in Asian and Latin American trials.

NeuroRx and Relief Therapeutics announced that they have successfully enrolled 165 patients as agreed with the US Food and Drug Administration (FDA) into an ongoing Phase IIb/III trial of RLF-100 (aviptadil) for treating respiratory failure in critical Covid-19 patients. Currently, there is no FDA-approved drug to treat these critical patients.

Canada has confirmed an order of 20 million doses of mRNA-1273, Moderna’s Covid-19 vaccine candidate, bringing the total confirmed purchase commitment to a total of 40 million doses. The vaccine was recently proved safe and efficacious in the Phase III COVE study.

According to official sources, Bharat Biotech has ought emergency use authorisation approval from India‘s drug regulator for Covaxin, its Covid-19 vaccine candidate. The Indian Council of Medical Research (ICMR) and Bharat Biotech have collaborated in the development of the of the vaccine